




CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA

The journal

Canadian Journal of Neurological Sciences

Volume 38 Number 5 September 2011



Revascularization for Complex Cerebral Aneurysms - Pages 712-718

Bai-Nan Xu, Zheng-Hui Sun, Chen Wu, Jin-Li Jiang, Ding-Biao Zhou,
Xin-Guang Yu, Garnette R. Sutherland, Bao-Min Li

Figure: Patient 1. Illustration of a large intracavernous aneurysm. A, B, C: Schematic illustration of the procedure. D: Preoperative MRI showing a right intracavernous ICA aneurysm. E: Preoperative 3D digital subtraction angiography showing an intracavernous aneurysm. F: Postoperative digital subtraction angiography showing a patent bypass vessel and no aneurysm.

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

Canadian Neurological Sciences Federation



46th Annual Congress

The Canadian Neurological Sciences Federation is pleased to recognize those Sponsors who are committed to supporting the 2011 Congress. These organizations partner with CNSF to determine the causes of, and develop treatment for diseases and injuries of the nervous system, and in the care of patients with these diseases and injuries.

<p>PLATINUM</p>  <p>MERCK Merck Frosst Canada Ltd., Kirkland, Quebec</p>	<p>PLATINUM</p>  <p>THE EPILEPSY COMPANY™</p>	<p>PLATINUM</p> 
<p>GOLD</p>  <p>Boehringer Ingelheim</p>	<p>GOLD</p>  <p>ALLERGAN INC. E-CPD CO-FOUNDING SPONSOR</p>	<p>GOLD</p>  <p>TEVA CANADA INNOVATION E-CPD CO-FOUNDING SPONSOR</p>
<p>SILVER</p> 	<p>SILVER</p>  <p>Talecris BIOTHERAPEUTICS</p>	<p>SILVER</p> 
<p>BRONZE</p> 		<p>BRONZE</p>  <p>Medtronic</p>

**NEUROLOGICAL SCIENCES
FOUNDATION OF CANADA**

- General Fund
- CNS - Don Paty Fund

SUPPORTERS

NOVARTIS PHARMACEUTICALS

EMD SERONO

BIOGEN IDEC

If you and your organization would like more information, or would like to discuss how you can partner with CNSF and meaningfully connect with our Congress delegates, please call or email Brett Windle, Corporate Development Coordinator at (403) 229-9544 or brett-windle@cnsfederation.org.

EDITORIALS

- 667** Safety, Not Only Efficacy Still to be Proven for Controversial New MS Treatment
Marcelo Kremenchutzky
- 669** Treating Intellectual Disability; Look for Creatine Peaks in the Brain
Asuri N. Prasad
- 671** Helping the FTD Patient-Caregiver Dyad
Gabriel C. Léger, Fadi Massoud

REVIEW ARTICLES

- 673** Delirium: A Review
Teneille Emma Gofton
- 681** Consciousness and Cell Memory: A Dynamic Epigenetic Interrelationship
Arthur J. Hudson
- 689** Rabies in the Critical Care Unit: Diagnostic and Therapeutic Approaches
Alan C. Jackson

HISTORICAL REVIEW

- 696** Neuroscience in Nazi Europe Part I: Eugenics, Human Experimentation, and Mass Murder
Lawrence A. Zeidman

ORIGINAL ARTICLES

- 704** Causes for Treatment Delays in Dystonia and Hemifacial Spasm: A Canadian Survey
Mandar Jog, Sylvain Chouinard, Doug Hobson, David Grimes, Robert Chen, Meetu Bhogal, Susan Simonyi
- 712** Revascularization for Complex Cerebral Aneurysms
Bai-Nan Xu, Zheng-Hui Sun, Chen Wu, Jin-Li Jiang, Ding-Biao Zhou, Xin-Guang Yu, Garnette R. Sutherland, Bao-Min Li
- 719** Prevalence of Childhood Epilepsy in Canada
A.N. Prasad, X. Sang, B.A. Corbett, J.G. Burneo

- 723** Depiction of Seizure First Aid Management in Medical Television Dramas
Andrew D. Moeller, Jeremy J. Moeller, Susan R. Rahey, R. Mark Sadler
- 728** Impact of the Cognitive Status on the Memory Complaints in MS Patients
M. Demers, I. Rouleau, P. Scherzer, J. Ouellet, C. Jobin, P. Duquette
- 734** Cyst Formation Following Radiosurgery for AVMs: Report of 3 Cases
Q. Al Hinai, D. Tampieri, L. Souhami, A. Sadikot, D. Sinclair, R. Leblanc
- 741** Complications in MS Patients after CCSVI Procedures Abroad (Calgary, AB)
Jodie M. Burton, Katayoun Alikhani, Mayank Goyal, Fiona Costello, Chris White, David Patry, Robert Bell, Michael D. Hill
- 747** Founder Mutation for α -sarcoglycan-LGMD2D in a Magdalen Islands Acadian Cluster
M. Tétreault, M. Srouf, J. Allyson, I. Thiffault, L. Loisel, Y. Robitaille, J.P. Bouchard, B. Brais
- 753** An International Needs Assessment of Caregivers for Frontotemporal Dementia
Tiffany W. Chow, Fabricio J. Pio, Kenneth Rockwood

NEUROIMAGING HIGHLIGHTS

- 758** Widespread Symmetrical Subcortical Band Heterotopia
Jason G. Emsley, Susan R. Rahey, R. Mark Sadler, Matthias H. Schmidt
- 760** Persistent Anterior Falcine Sinus: Demonstration by CT Angiography
Charles C. Matouk, Daniel M. Mandell, Timo Krings, Robert A. Willinsky, Karel G. terBrugge

BRIEF COMMUNICATIONS

- 762** Missing Huntington's Disease for Tardive Dyskinesia: A Preventable Error
Hrishikesh Kumar, Mandar Jog

- 765** Creatine Deficiency Syndromes: Diagnostic Pearls and Pitfalls

Claire Hinnell, Michael Samuel, Fadi Alkufri, Keyoumars Ashkan, Yusof Rahman, Charles Turner, R. Neil Dalton, Lina Nashef

- 768** OFF-Rebound Dyskinesia in Subthalamic Nucleus Stimulation in Parkinson Disease

Jee-Young Lee, Han-Joon Kim, Ji Young Yun, Sun Ha Paek, Beom S. Jeon

- 772** Glucocerebrosidase Mutations in a French-Canadian Parkinson's Disease Cohort

Anne Noreau, Jean-Baptiste Rivière, Sabrina Diab, Patrick A. Dion, Michel Panisset, Valérie Soland, Nicolas Jodoin, Mélanie Langlois, Sylvain Chouinard, Nicolas Dupré, Guy A. Rouleau

- 774** Multiple Brain Cysts: An Unusual Form of Demyelinating Disease

Mario Habek, Ivan Adamec, Kamelija Žarković, David Ozretić, Vesna V. Brinar

COMMENTARY

- 777** New Anticoagulants for Atrial Fibrillation: The Beginning of A New Era in Stroke Prevention

David J. Gladstone, Karen M. Earl, Tammy J. Bungard, Jafna L. Cox, Alan Bell, Paul Dorian, Naeem Dean, Thao Huynh, Anil Chopra, John Eikelboom, Ashfaq Shuaib

- 783** Health Research Funding in Crisis

Michael O. Poulter, G. Bryan Young

LETTERS TO THE EDITOR

- 785** To the Editor - More Than 'Answers We Can Use', We Need to Ask the Right Questions

Re: Pelz D. CURES and the dilemma of unruptured intracranial aneurysms. *Can J Neuro Sci.* 2011 Mar;38(2):191-2.

Tim. E. Darsaut, Jean Raymond, J. Max Findlay

- 785** To the Editor - Unruptured Intracranial Aneurysms: Some Questions Answered, Many Questions Remain

Re: Pelz D. CURES and the dilemma of unruptured intracranial aneurysms. *Can J Neuro Sci.* 2011 Mar;38(2):191-2.

Robert D. Brown, James Torner

- 787** To the Editor - Ethanol Abuse After a Right Temporal Lobe Resection for Intractable Epilepsy

Farzad Moien-Afshari, José F. Téllez-Zenteno

- 788** To the Editor - A Case of Bilateral Homonymous Hemianopsia with Macular Sparing

Anne-Marie Dufresne, Martin Savard

- 790** To the Editor - Paraneoplastic Encephalomyelitis, Stiff Person Syndrome and Breast Carcinoma

Julie Lemieux, Louise Provencher, Denis Brunet, Jean-Charles Hogue

- 792** To the Editor - A Case of Phenytoin-Induced Encephalopathy in a Mathematician with Stage IV NSCLC

Carmela Pepe, Caroline Marchionni

- 794** To the Editor - Spinal Cord Injury after Prolonged Neck Flexion, is it an Underestimated Risk?

Hussein Alahmadi, Gelareh Zadeh

- 796** To the Editor - Isolated Unilateral Hypoglossal Nerve Palsy

Daniel Mendelsohn, Faizal Haji, Wai P. Ng

- 797** To the Editor - Melanoma-Associated Retinopathy Report of a Case and Review

H. Bahig, F. Wein, R.F. Del Maestro

- 799** Books Received/Books Reviewed

IFC CNSF Sponsors

A-9 Congress Thank You

A-11/12 Information for Authors

A-12 Advertisers Index


A-23 CNS Lifetime Achievement Award -
Dr. Henry J.M. Barnett

A-23 Erratum

ARAC - The Montreal Jewish General Hospital Alzheimer Risk Assessment Clinic
Can J Neurol Sci. 2011 Jul;38(4):600-11.

A-26/27 Classified Ads

A-28 Board of Directors/Committee Chairs



We're committed to offering you more.

At Scotiabank, we have experts that can help you grow your practice. *Scotia Professional*[®] Plan is a customized financial package that includes everything you need to start and run a successful business.

Our advisors go above and beyond the financial services you'd expect from a bank. We're committed to offer more tools, resources, advice, and of course, banking packages like Scotia Professional Plan – to help you grow your practice.

It's our promise. No other bank does that.

Find out how we offer more. Talk to a Scotiabank Small Business advisor today or visit scotiabank.com/professional.

Scotia Professional Plan

You're richer than you think.[®]



Cymbalta®: Third Analgesic Indication¹
**CHRONIC LOW BACK
PAIN**

Cymbalta® is also an analgesic for use in:¹

- Diabetic Peripheral Neuropathic Pain
- Pain associated with Fibromyalgia

Covered by most private and some public drug plans. See DrugCoverage.org for details. DIN: 02301490.



© Eli Lilly Canada Inc., Toronto, Ontario, M1N 2E8
* Licensed user of trademark owned by Eli Lilly and Company.

1-866-364-4043
www.lillyinteractive.ca

The Cymbalta logo features a stylized graphic of three curved lines in blue and green, resembling a globe or a cluster of cells.

Cymbalta® DELAYED
RELEASE
CAPSULES
duloxetine HCl

The Lilly logo is the word 'Lilly' written in a red, cursive script font.

All patients who participated in the chronic low back pain clinical trials had a clinical diagnosis of CLBP with pain present on most days for at least 6 months and no signs of radiculopathy or spinal stenosis.¹

Cymbalta® (duloxetine hydrochloride) is indicated for the management of chronic low back pain (CLBP).¹

Cymbalta® is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN).¹

Cymbalta® is indicated for the management of pain associated with fibromyalgia (FM).¹

The efficacy of Cymbalta® has been demonstrated in controlled clinical trials for up to 12 weeks in DPN and FM and up to 13 weeks in patients with CLBP. The physician who elects to use Cymbalta® for extended periods in DPN, FM or CLBP should periodically re-evaluate the long-term usefulness of the drug for the individual patient.¹

Cymbalta® is not indicated for use in children under 18 years of age.¹

Rigorous clinical monitoring for suicidal ideation or other indicators of potential for suicidal behaviour is advised in patients of all ages. This includes monitoring for agitation-type emotional and behavioural changes. Please see Prescribing Information for complete warnings.¹

Patients currently taking Cymbalta® should NOT be discontinued abruptly due to risk of discontinuation symptoms. A gradual reduction in the dose is recommended.¹

Cymbalta® is contraindicated in patients with a known hypersensitivity to the drug or the other components of the product.¹

Cymbalta® is contraindicated in patients with end-stage renal disease (requiring dialysis) or with severe renal impairment (estimated creatinine clearance <30 mL/min).¹

Cymbalta® is contraindicated in patients with any liver disease resulting in hepatic impairment.¹

Cymbalta® is contraindicated in patients concomitantly taking any of the following medications: monoamine oxidase inhibitors (MAOI), including the antibiotic linezolid and the thiazine dye methylthionium (methylene blue) which are less well-known examples of MAOIs, or within at least 4 days of discontinuing treatment with an MAOI; potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin); and thioridazine.¹

Cymbalta® is contraindicated in patients with uncontrolled narrow-angle glaucoma.¹

The most commonly observed adverse events in Cymbalta®-treated CLBP patients (incidence 5% or greater and at least twice the incidence in placebo patients) included nausea (16%), dry mouth (9%), insomnia (8%), somnolence (8%), constipation (7%), fatigue (6%), and dizziness (6%).¹

Please see Product Monograph for complete prescribing details including warnings, precautions, adverse events, dosing, administration and indications.





1. Cymbalta® Product Monograph. Eli Lilly Canada Inc., April 8, 2011.



CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA

**Thank you delegates for joining us at
this years CNSF Congress in
Vancouver!**

**We look forward to seeing you at our
2012 Congress in Ottawa, Ontario!**



See prescribing summary of pages A-15 to A-18



*Fictitious patient. May not be representative of all fibromyalgia cases.



FACED WITH PAIN*

IN HER STRUGGLE WITH FIBROMYALGIA

First treatment indicated in Canada for adults for the management of pain associated with

fibromyalgia¹

Pregabalin: first-line treatment for chronic **neuropathic pain²**

DEMONSTRATED SIGNIFICANT RELIEF IN PAIN AND PAIN-RELATED SLEEP DIFFICULTIES IN FIBROMYALGIA¹

Demonstrated powerful, rapid and sustained pain relief^{1,3-5}

In fibromyalgia:

- In a 14 week study, LYRICA demonstrated significant pain reduction as early as week 1 ($p < 0.05$ for all doses). Mean changes in pain scores at the end of the study for LYRICA-treated patients were significantly greater versus placebo (300 mg/day, $n=183$: -1.75, $p=0.0009$; 450 mg/day, $n=190$: -2.03, $p < 0.0001$; 600 mg/day, $n=188$: -2.05, $p < 0.0001$; placebo, $n=184$: -1.04)³
- In another study of 26 weeks' duration of patients who initially responded to LYRICA during a 6-week, open-label phase, 68% of those who continued on their optimized dose ($n=279$) maintained a treatment response versus 39% of those on placebo ($n=287$). The time to loss of therapeutic response was longer in the LYRICA group ($p < 0.0001$)⁴

Also in neuropathic pain (NeP):

- Sustained pain relief (starting at week 2 for LYRICA 150-600 mg/day, $n=141$; $p < 0.05$ vs placebo, $n=65$) was demonstrated throughout a 12 week study in patients with DPN or PHN⁵

Demonstrated effective in relieving pain-related sleep difficulties^{1,6}

In fibromyalgia:

- In a 13 week study, LYRICA reduced overall MOS-Sleep Scale scores significantly more at the end of the study vs. placebo (300 mg/day -19.1, $p=0.0174$; 450 mg/day: -20.41, $p=0.0026$; 600 mg/day: -19.49, $p=0.0101$; placebo: -14.29)⁶

Also in NeP:

- LYRICA reduced sleep disturbances across several studies in DPN and PHN, of 8-12 weeks duration¹

Flexible dosing across all indications^{1†}

LYRICA (pregabalin) is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN) and spinal cord injury in adults. LYRICA may be useful in the management of central neuropathic pain in adults. LYRICA is indicated for the management of pain associated with fibromyalgia in adults. The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase.

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

The most commonly observed adverse events ($\geq 5\%$ and twice the rate as that seen with placebo) in the recommended dose range of 150 mg/day to 600 mg/day in PHN and DPN patients were: dizziness (9.0-37.0%), somnolence (6.1-24.7%), peripheral edema (6.1-16.2%), and dry mouth (1.9-14.9%) and were dose related; in spinal cord injury patients: somnolence (41.4%), dizziness (24.3%), asthenia (15.7%), dry mouth (15.7%), edema (12.9%), constipation (12.9%), amnesia (10.0%), myasthenia (8.6%), amblyopia (8.6%), and thinking abnormal (8.6%); in fibromyalgia patients: dizziness (37.5%), somnolence (18.6%), weight gain (10.6%), dry mouth (7.9%), blurred vision (6.7%), and peripheral edema (6.1%). In LYRICA-treated fibromyalgia patients, the most commonly observed dose-related adverse events were: dizziness (22.7-46.5%), somnolence (12.9-20.7%), weight gain (7.6-13.7%), peripheral edema (5.3-10.8%). The most commonly observed adverse events in the PHN, DPN, spinal cord injury and fibromyalgia patients were usually mild to moderate in intensity. Discontinuation rates due to adverse events for LYRICA and placebo, respectively, were 9% and 4% in DPN, 14% and 7% in PHN, 21% and 13% in spinal cord injury, and 20% and 11% in fibromyalgia. There was a dose-dependent increase in rate of discontinuation due to adverse events in fibromyalgia.

There have been post-marketing reports of angioedema in patients, some without reported previous history/episodes, including life-threatening angioedema with respiratory compromise. Caution should be exercised in patients with previous history/episodes of angioedema and in patients who are taking other drugs associated with angioedema.

In clinical trials and in post-marketing experience, there have been reports of patients, with or without previous history, experiencing renal failure alone or in combination with other medications. Caution is advised when prescribing to the elderly or those with any degree of renal impairment.

There have been post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, and constipation) in patients, some without reported previous history/episode(s), during initial/acute and chronic treatment with LYRICA, primarily in combination with other medications that have the potential to produce constipation. Some of these events were considered serious and required hospitalization. In a number of instances, patients were taking opioid analgesics including tramadol. Caution should be exercised when LYRICA and opioid analgesics are used in combination, and measures to prevent constipation may be considered, especially in female patients and elderly as they may be at increased risk of experiencing lower gastrointestinal-related events.

Dosage reduction is required in patients with renal impairment (creatinine clearance <60 mL/min) and in some elderly patients as LYRICA is primarily eliminated by renal excretion.

Please see Prescribing Information for complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria.


† Please consult Prescribing Information for complete Dosage and Administration instructions.



Working together for a healthier world™

©2010
Pfizer Canada Inc.
Kirkland, Quebec
H9J 2M5

™Pfizer Inc, used under license
LYRICA® C.P. Pharmaceuticals International C.V.,
owner/Pfizer Canada Inc., Licensee



Editor-in-Chief/Rédacteur en chef

G. Bryan Young LONDON, ON

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB
Michael Shevell MONTREAL, QC
Timothy J. Benstead HALIFAX, NS
Mike Poulter LONDON, ON
Serge Gauthier VERDUN, QC
Robert Hammond LONDON, ON

Past Editors/Anciens rédacteurs en chef

Douglas W. Zochodne CALGARY, AB
James A. Sharpe TORONTO, ON
Robert G. Lee CALGARY, AB
Robert T. Ross WINNIPEG, MB
(Emeritus Editor, Founding Editor)

Editorial Board/Conseil d'éditorial

Jorge Burneo LONDON, ON
Richard Desbiens QUEBEC CITY, QC
David Fortin SHERBROOKE, QC
Mark Hamilton CALGARY, AB
Hans-Peter Hartung DUSSELDORF, GERMANY
Michael Hill CALGARY, AB
Alan C. Jackson WINNIPEG, MB
Daniel Keene OTTAWA, ON
Terence Myles CALGARY, AB
James Perry TORONTO, ON
Oksana Suchowersky CALGARY, AB
Brian Toyota VANCOUVER, BC
Brian Weinshenker ROCHESTER, MN, USA
Samuel Wiebe CALGARY, AB
Elaine Wirrell ROCHESTER, MN, USA

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie

David Pelz LONDON, ON

**Neuropathological Conference/Conférence
sur la neuropathologie**

Robert Hammond LONDON, ON

**Book Review/Critiques de livres
Reflections/Reflets**

Andrew Kirk SASKATOON, SK

**Critically Appraised Topic Summaries
(CATS)**

Jorge Burneo LONDON, ON
Mary Jenkins LONDON, ON

**Editorial Review Board/Conseil de
Revue d'éditorial**

Donald Brunet KINGSTON, ON
Lionel Carmant MONTREAL, QC
Colin Chalk MONTREAL, QC
K. Ming Chan EDMONTON, AB
Robert Chen TORONTO, ON
Mary Connolly VANCOUVER, BC
Joseph Dooley HALIFAX, NS
Paolo Federico CALGARY, AB
Daryl Fourney SASKATOON, SK
Hannah Glass SAN FRANCISCO, CA, USA
Alan Goodridge ST. JOHN'S, NL
Ian Grant HALIFAX, NS
Alan Guberman OTTAWA, ON
John Hurlbert CALGARY, AB
Manouchehr Javidan VANCOUVER, BC
Patrick McDonald WINNIPEG, MB
Martin McKeown VANCOUVER, BC
Joseph Megyesi LONDON, ON
Vivek Mehta EDMONTON, AB
Steven Miller VANCOUVER, BC
Neelan Pillay CALGARY, AB
Christopher Power EDMONTON, AB
Alex Rajput SASKATOON, SK
Jean Raymond MONTREAL, QC
Gary Redekop VANCOUVER, BC
Mark Sadler HALIFAX, NS
Harvey Sarnat CALGARY, AB
John Stewart VANCOUVER, BC
Jeanne Teitelbaum MONTREAL, QC
Eve Tsai OTTAWA, ON
Shannon Venance LONDON, ON
Matt Wheatley EDMONTON, AB
Jerome Yager EDMONTON, AB

Journal Staff - Calgary, AB

Dan Morin, *Chief Executive Officer*
Maggie McCallion, *Designer/*
Production Coordinator
Cindy Leschyshyn, *Editorial Coordinator*

**Advertising representative/Représentant de
publicité:**

Brett Windle
Corporate Development Coordinator
Tel (403) 229-9575 Fax (403) 229-1661
E-mail: brett-windle@cnsfederation.org

Printer/Imprimeur:

Unicom Graphics, 4501 Manitoba Road SE
Calgary, Alberta T2G 4B9

The official journal of: / La Revue officielle de:

**The Canadian Neurological Society
La Société Canadienne de Neurologie**

**The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie**

**The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique**

**The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at:
Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est situé en permanence à:


7015 Macleod Trail SW, Suite 709
Calgary, Alberta, Canada T2H 2K6

The Canadian Journal of Neurological Sciences is published bi-monthly. The annual subscription rate for Individuals are: C\$120 (Canada), C\$140 (Foreign including USA). Subscription rates for Institutions are: C\$150 (Canada), C\$170 (Foreign including USA). See www.cjns.org for details. Single copies C\$30 each plus postage and handling. Communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: journal@cjns.org; Web: www.cjns.org
COPYRIGHT © 2011 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Postage paid at Calgary, Alberta.

Le Journal Canadien des Sciences Neurologiques est publié 6 fois par an. L'abonnement annuel est de 120 \$C (non-membres au Canada); 140 \$C (Etats Unis et ailleurs); l'abonnement annuel pour les institutions est de 150 \$C (non-membres au Canada); 170 \$C (Etats Unis et ailleurs); Voir www.cjns.org pour détails. Copie simple: 30 \$C plus affranchissement et manutention. Toutes les communications doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail journal@cjns.org; Web: www.cjns.org. DROITS D'AUTEUR © 2011: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Port payé à Calgary, Alberta.

This journal is indexed by / Cette Journal est cité et indexé dans:
AgBio, BIOBASE, BioAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, E-psyche, EBSCO, Elsevier, EMBASE, ExcerptMed, IBZ, Index Medicus, Index to Dental Literature, Index to Scientific Reviews, Inpharma, Internationale Bibliographie der Rezensionen Geistes- und Sozialwissenschaftlicher Literatur, JW-N, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, Personal Alert, PsycFIRST, PsycInfo, Psychological Abstracts, PubMed, Reac, RefZh, SCI, SCOPUS, Swets, TOCpre, Web of Science
ADVERTISING.

ISSN 0317 - 1671





CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA



The Canadian Neurological Sciences Federation would like to graciously acknowledge and thank the following for their commitment and participation in the highly successful 46th Annual Congress held this past June 15 – 17, 2011 in Vancouver, B.C.

Scientific Program & Professional Development Committees

Michael Hill (Chair, SPC)	Jeanne Teitelbaum (SPC)	Michelle Demos (SPC)
Colin Chalk (Chair, PDC)	R. Loch Macdonald (Vice Chair, SPC)	Jennifer Gelinas (SPC, PDC)
Ron Pokrupa (Vice Chair, PDC)	Derek Fewer (SPC)	Garth Bray (PDC)
Cecil Hahn (SPC)	Chris White (SPC)	Bev Prieur (PDC)
Seyed Mirsattari (SPC)	Trevor Steve (SPC, PDC)	Martin del Campo (PDC)
Shobhan Vachhrajani (SPC, PDC)	Eric Massicotte (SPC)	John Stewart (SPC)
J. Max Findlay (SPC)	James Perry (SPC)	Rudolf Arts (PDC)

Distinguished Guest Lecturer

André Picard

Plenary Speakers

William Couldwell
Judy Illes

Ingrid Scheffer
Allan Taylor

Angela Vincent

Session Chairs and Platform & Poster Moderators

S. Nizam Ahmed	Derek Fewer	Sarah Kirby	Mike Nicolle	Jeanne Teitelbaum
Ryojo Akagami	William Fletcher	Zelma Kiss	Gwynedd Pickett	Mike Tymianski
Ming Chan	Cecil Hahn	R. Loch Macdonald	Alex Rajput	Brian Toyota
Kristine Chapman	Mark Hamilton	Gordon Mackie	Gary Redekop	Anthony Traboulsee
Mary Connolly	Michael Hill	Eric Massicotte	Gordon Robinson	Shobhan Vachhrajani
Silke Appel-Cresswell	Chris Honey	Richard McLachlan	Ramesh Sahjapaul	Lyle Weston
Michelle Demos	Ging-Yuek Robin Hsiung	Rajiv Midha	Peter Smith	Sharon Whiting
David Eisenstat	Draga Jichici	Seyed Mirsattari	John Stewart	

Session Speakers

Jacob Alant	Richard Fox	Line Jacques	Vivek Mehta	Petra Schweinhardt
Nigel Ashworth	J. Alexander Fraser	Draga Jichici	David Mercier	Ashfaq Shuaib
Jason Barton	Jan Friedman	John A. Kiernan	Seyed Mirsattari	Sian Spacey
Werner Becker	Kazuo Fujihara	Zelma Kiss	Mark Morrow	Dennis Spencer
Michael Benatar	Peter Gooderham	Miche Kliot	Richard Moulton	David Steven
Charles Bolton	Prenesh Govender	Joel Kramer	Alan Nichol	Jon Stoessl
Tiffany Chow	Donald Gross	Andrei Krassioukov	Mike Nicolle	Philip Teal
Brian Christie	Morris Groves	Mohamed Labib	Joel Oger	Jeanne Teitelbaum
Mary Connolly	Manraj Heran	Sylvain Lanthier	Michael O. Poulter	Brian Toyota
Fiona Costello	Marie-Noelle Herbert-	Liesly Lee	Jacqueline Quandt	Anthony Traboulsee
Bruce Cree	Blouin	Stan Leung	Gary Redekop	Matt Wheatley
Mark Cresswell	Michael Hill	David Li	Jong Rho	John Wong
Tim Darsaut	Mojgan Hodaie	Ian Mackenzie	Lawrence Richer	Stephen Yip
Virginia Devonshire	Chris Honey	Gordon Mackie	Dessa Sadovnick	Bryan Young
Cameron Elliot	Ging-Yuek Robin Hsiung	Tom Marotta	Ramesh Sahjapaul	Gelareh Zadeh
Aria Fallah	Judy Illes	Eric Massicotte	Ana-Luiza Sayeo	Thomas Zwimpfer
William Fletcher	Brad Jacobs	Patrick McDonald	Ingrid Scheffer	

Effective Tax Planning

Creating financial plans to help you achieve optimal business results is a task that may not be at the top of your daily to-do list, but having a plan can make a significant impact on reaching your personal long-term goals. Tax planning is a key consideration for any business owner, and certainly for Neurologists.

Effective tax planning must factor in both business and personal aspects of your situation. We've highlighted some occasionally overlooked tax-effective methods for building your personal wealth using the proceeds of your ongoing business activities. Done effectively, you'll enhance your company's cash flow and leave yourself with significantly enhanced retirement savings. Here are some ideas to discuss with your financial advisor.

Think of the Dividends

Rather than just a salary, consider receiving a portion of your pay in dividends. This allows for greater freedom in determining the income split between you and your spouse. It also saves on CPP premiums, a valuable benefit, since as an entrepreneur you have to pay both the employer's and the employee's share of contributions. Dividends also offer more flexibility in terms of when to receive payments.

Qualify for the Low Small Business Tax Rate

In most provinces, small businesses with an annual pre-tax income of \$500,000 or less pay a significantly lower rate of tax than regular corporations. (In some provinces, the lower tax rate only applies if pre-tax income is \$400,000 or less.) Time your deductible expenses, investments, and draw the appropriate type and level of income, in order to keep your operation's annual taxable income below the ceiling.

Consider a Higher Salary or Income Splitting

You may regularly only pay yourself what you need for living expenses in order to minimize personal taxes. However, paying yourself a larger salary can actually have two valuable benefits:

- **More RRSP Room:** The higher your salary, the more you can contribute to a Registered Retirement Savings Plan. Currently, the salary required to contribute the maximum amount of \$22,450 to ones RRSP is roughly \$122,000.
- **Lower Business Taxes:** Boosting your salary can help reduce your corporate income below the \$500,000 small business threshold, meaning you'll enjoy a substantially lower corporate tax rate. Be mindful to take into consideration, the personal tax payable as a result. It is highly advised that you consult with a qualified accountant to help navigate through your own unique circumstances.

Revisit Your Corporate Structure

As your business prospers, reorganizing can often reap immediate and in some cases, significant tax savings and help you save more for your retirement. This may involve setting up both another operating company as well as adding a holding company to invest the businesses retained profits. A family trust is also often used for creditor protection of assets and gives you the added benefit of splitting income amongst family members, and is also an excellent planning tool used on the future sale of shares of the company, as it offers the possibility of creating separate capital gains exemptions for the beneficiaries of the trust.

Use a Tax-Free Savings Account

From a personal tax perspective, If you have money left over after maximizing your RRSP contributions, consider opening or depositing money into a Tax-Free Savings Account. You can contribute up to maximum of \$5,000 a year into a TFSA. (Take note however, unlike an RRSP, your contributions aren't tax-deductible).

The advantage is that there is no tax on profits you earn inside this account, regardless of whether it's in the form of interest, dividends, or capital gains. And there is no tax due on funds withdrawn from a TFSA, including both your original contributions as well as gains earned inside the plan.

Used alone or in combination, these strategies will help you reduce taxes while investing for the future. Speak to a Scotiabank advisor about optimizing your results with effective tax planning.

Scotia Professional Plan

www.scotiabank.com



www.scotiabank.com

This publication has been prepared by ScotiaMcLeod, a division of Scotia Capital Inc.(SCI), a member of CIPF. This publication is intended as a general source of information and should not be considered as personal investment, tax or pension advice. We are not tax advisors and we recommend that individuals consult with their professional tax advisor before taking any action based upon the information found in this publication. This publication and all the information, opinions and conclusions contained in it are protected by copyright. This report may not be reproduced in whole or in part, or referred to in any manner whatsoever, nor may the information, opinions, and conclusions contained in it be referred to without in each case the prior express consent of SCI. Scotiabank Group refers to The Bank of Nova Scotia and its domestic subsidiaries. © Registered trademark of The Bank of Nova Scotia, used by ScotiaMcLeod under license. ScotiaMcLeod is a division of Scotia Capital Inc. Scotia Capital Inc. is a Member-Canadian Investor Protection Fund.